dr. pennell on the risks associated with sequential therapy with immunotherapy/tkis in lung cancer
Published 4 years ago • 103 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:22
dr. pennell on challenges with ngs in lung cancer
-
2:22
dr. pennell on the evolution of targeting her2 in lung cancer
-
2:10
dr. pennell on unique treatment-related toxicities in lung cancer
-
1:42
dr. bazhenova on sequential use of immunotherapy and egfr tkis in lung cancer
-
1:41
dr. pennell on remaining challenges in nsclc
-
1:13
dr. pennell on the economic impact of next-generation sequencing
-
2:10
dr. pennell on importance of egfr testing in nsclc
-
1:39
dr. pennell on benefits of liquid biopsies in lung cancer
-
2:17
nathan pennell, md, phd | cleveland clinic hematology & oncology
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
2:32
what side effects can be associated with immunotherapy for lung cancer?
-
0:30
emerging data on immunotherapies and tyrosine kinase inhibitors in lung cancer: 2022 esmo florida
-
4:16
upfront pd-1 inhibitor monotherapy in advanced nsclc
-
4:19
toxicities in treatments of lung cancers with respect to the elderly
-
1:30
dr. papadimitrakopoulou on impactful targeted therapies in lung cancer
-
0:59
dr. alva on tki monotherapy and combinations for rcc
-
1:03:33
weekly webinar series part 8: managing lung cancer patients through the covid-19 pandemic
-
3:45
pennell the role for immunotherapy in patients with a driver mutation
-
1:34
dr. pennell on the use of brigatinib in alk nsclc